🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesCoronary artery calcium score changes on GLP-1 — my results so far Page 2

Coronary artery calcium score changes on GLP-1 — my results so far

carl_compliance Sat, Oct 4, 2025 at 8:59 PM 10 replies 1,250 viewsPage 2 of 2
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Oct 5, 2025 at 12:09 AM#6
JessicaH_TX said:
I want to bring up the cardiovascular angle on cardiovascular risk.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

5 8BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 2 others
Reply Quote Save Share Report
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Oct 5, 2025 at 1:23 AM#7
carl_compliance said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 60 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: Oct 5, 2025 at 5:23 AM
6 9NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 3 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Oct 5, 2025 at 2:37 AM#8
DebRD_ATL said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

7 10AussieAnna, BethLabQueen, ChrisMacros and 4 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Oct 5, 2025 at 3:51 AM#9

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

Last edited: Oct 5, 2025 at 6:51 AM
8 11InsuranceTom, WendyG_ATL, SaraMom3 and 5 others
Reply Quote Save Share Report
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Oct 5, 2025 at 9:47 AM#10
anders_CPH said:
NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

10 months later: down 57 lbs, off metoprolol, A1C from 7.4% to 5.2%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

14 14dave_SLC, FDA_TrackerJim, ricardo_MIA and 11 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register